불면증 신규 치료법 보고서(2026년)(2분기판)

The Global Insomnia Emerging Therapies Market is anticipated to grow at a CAGR of 33.7% from USD 398.43 million 2026 to USD 5,440.68 million in 2035.

The emerging therapy landscape is evolving rapidly as pharmaceutical and biotechnology companies develop innovative therapies designed to improve both nighttime sleep quality and daytime functioning while minimizing the risk of dependence and residual sedation.

Insomnia is one of the most prevalent sleep disorders worldwide, affecting millions of individuals and significantly impacting mental health, cardiovascular health, cognitive performance, workplace productivity, and overall quality of life. Although conventional pharmacological therapies and cognitive behavioral therapy for insomnia (CBT-I) remain important treatment options, unmet clinical needs continue to drive innovation toward novel therapies with improved safety, efficacy, and long-term outcomes. Emerging therapies analysis provides comprehensive insights into investigational products, clinical development phases, mechanisms of action, sponsor activities, regulatory progress, and future commercialization opportunities.

Market Drivers

Growing Demand for Novel Mechanism-Based Therapies

Concerns regarding dependence, tolerance, and next-day residual effects associated with traditional sleep medications are increasing demand for therapies that target the biological mechanisms regulating sleep and wakefulness. Orexin-based therapies are emerging as one of the most promising approaches in the insomnia pipeline.

Increasing Recognition of Chronic Insomnia

Healthcare providers increasingly recognize insomnia as a chronic neurological condition rather than a temporary sleep complaint. Earlier diagnosis and greater awareness are expanding the eligible patient population and encouraging investment in innovative therapeutic development.

Expansion of Precision Medicine

Advances in sleep neuroscience, biomarkers, artificial intelligence, and digital health technologies are supporting more personalized approaches to insomnia treatment and improving clinical trial design.

Growing Focus on Functional Outcomes

Regulatory agencies and healthcare providers are placing greater emphasis on therapies that improve daytime functioning, cognition, quality of life, and overall patient well-being in addition to sleep initiation and maintenance.

Market Restraints

Stringent Long-Term Safety Requirements

Emerging insomnia therapies require extensive long-term clinical evidence demonstrating sustained efficacy, favorable safety profiles, and low abuse potential before regulatory approval.

Competition from Established Therapies

Widely available generic sleep medications and the continued recommendation of cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment create competitive pressure for emerging pharmacological therapies.

Pricing and Reimbursement Challenges

Healthcare payers increasingly evaluate comparative effectiveness and long-term value before providing reimbursement for premium-priced innovative insomnia treatments.

Emerging Therapy and Technology Insights

The global insomnia emerging therapies market can be segmented by development phase, mechanism of action, modality, therapy focus, and geography.

By development phase, the market includes preclinical pipeline, Phase I, Phase II, Phase III, and filed/under regulatory review assets. Clinical activity continues to expand as multiple investigational therapies advance through late-stage development while early-stage programs explore novel biological targets.

By mechanism of action, emerging therapies include orexin-based therapies, GABAergic therapies, circadian rhythm modulators, melatonin-based therapies, and novel mechanism-based therapies. Orexin receptor modulation remains the leading area of innovation due to its differentiated mechanism and favorable clinical profile.

By modality, the pipeline consists of small molecules, biologics, RNA therapies, cell therapies, and gene therapies. Small molecules currently dominate clinical development, while advanced therapeutic platforms continue to gain research interest.

By therapy focus, investigational products target sleep initiation, sleep maintenance, dual-benefit therapies addressing both outcomes, and therapies designed to improve daytime functioning. Growing emphasis on comprehensive patient outcomes is reshaping clinical development priorities.

Technological advances including artificial intelligence-assisted drug discovery, wearable sleep monitoring devices, digital biomarkers, decentralized clinical trials, real-world evidence platforms, and advanced sleep analytics continue to improve target identification, patient selection, and development efficiency.

Emerging Therapy Development Trends

The insomnia emerging therapy landscape continues to evolve toward mechanism-driven innovation and personalized sleep medicine.

Key development trends include:

• Expansion of orexin receptor-targeted therapies.
• Growing investment in circadian rhythm modulation.
• Increasing emphasis on therapies with improved daytime functioning.
• Wider integration of artificial intelligence into drug discovery.
• Greater use of patient-reported outcome measures in clinical development.
• Expansion of precision medicine and biomarker-guided treatment approaches.
• Increasing focus on patients with comorbid neurological and psychiatric disorders.

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and research organizations continue to accelerate innovation while strengthening the global insomnia pipeline.

Regional Insights

North America remains the leading region for insomnia emerging therapies due to advanced sleep medicine infrastructure, strong pharmaceutical research activity, high diagnosis rates, and favorable regulatory support for innovative neurological therapies.

Europe continues to play an important role through established sleep research centers, collaborative neuroscience programs, and structured regulatory pathways supporting innovation.

Asia-Pacific is expected to experience the fastest growth during the forecast period owing to expanding healthcare infrastructure, increasing awareness of sleep disorders, rising pharmaceutical investment, and growing clinical research activity across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening market opportunities through improved healthcare access, expanding sleep medicine services, and increasing recognition of insomnia as a significant public health concern.

Competitive Landscape

The insomnia emerging therapies landscape includes multinational pharmaceutical companies, biotechnology firms, specialty neuroscience developers, academic research institutions, and digital health innovators.

Companies continue investing in orexin receptor modulation, circadian rhythm biology, precision medicine, artificial intelligence-enabled drug discovery, and digital sleep technologies. Strategic licensing agreements, research collaborations, mergers and acquisitions, and commercialization partnerships remain key strategies for accelerating therapeutic development and expanding market presence.

Future Outlook

The future of the insomnia emerging therapies market is expected to be shaped by advances in sleep neuroscience, precision medicine, artificial intelligence, and digital health technologies. Future therapeutic innovation will increasingly focus on biologically targeted treatments capable of delivering durable improvements in both sleep quality and daytime functioning while minimizing adverse effects and dependence risks.

Growing integration of biomarkers, wearable monitoring technologies, real-world evidence, and patient-centered outcome measures is expected to improve clinical development efficiency while supporting broader regulatory approvals and commercialization opportunities.

Conclusion

The global Insomnia Emerging Therapies Analysis market is expected to experience substantial growth through 2035, supported by increasing recognition of chronic insomnia, expanding investment in mechanism-based drug development, advances in sleep neuroscience, and growing demand for innovative therapies with improved safety profiles. Although challenges related to long-term safety requirements, reimbursement pressures, and competition from existing treatments remain, continued innovation in orexin biology, circadian rhythm modulation, artificial intelligence, and precision medicine is expected to transform the future insomnia treatment landscape.

Key Benefits of this Report

• Comprehensive analysis of the global insomnia emerging therapies landscape and future innovation trends.
• Detailed evaluation of investigational therapies, mechanisms of action, and clinical development progress.
• Competitive assessment of pipeline assets, sponsor activities, and strategic collaborations.
• Insights into regulatory developments, commercialization opportunities, and future therapeutic strategies.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline benchmarking, competitive intelligence, licensing and partnership evaluation, portfolio optimization, investment analysis, commercialization planning, clinical development strategy, regulatory planning, and identification of future market opportunities.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the insomnia emerging therapies landscape by development phase, mechanism of action, modality, therapy focus, and geography
• Evaluation of investigational therapies, clinical development progress, pipeline maturity, and innovation trends
• Assessment of sponsor activities, strategic collaborations, licensing agreements, regulatory developments, and competitive positioning
• Analysis of orexin-based therapies, circadian rhythm modulators, artificial intelligence-driven drug discovery, precision medicine, and future commercialization opportunities through 2035

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Emerging Therapies Pipeline Snapshot
  • 1.1.1 Global Emerging Therapies Landscape Overview
  • 1.1.2 Active Emerging Assets by Development Stage
  • 1.1.3 Key Emerging Mechanisms Driving Innovation
  • 1.1.4 Clinical Development Momentum Assessment
  • 1.1.5 Near-Term Value Creation Opportunities
• 1.2 Strategic Insights
  • 1.2.1 Most Promising Emerging Assets
  • 1.2.2 High-Probability Clinical Success Candidates
  • 1.2.3 Emerging Competitive Threats
  • 1.2.4 Regulatory Milestone Outlook
  • 1.2.5 Investment and Partnership Trends
• 1.3 Key Conclusions
  • 1.3.1 Pipeline Maturity Assessment
  • 1.3.2 Innovation Outlook
  • 1.3.3 Commercialization Readiness Outlook

2. Pipeline Overview

• 2.1 Global Insomnia Emerging Therapies Landscape
  • 2.1.1 Historical Evolution of Insomnia Drug Development
  • 2.1.2 Current Emerging Pipeline Composition
  • 2.1.3 Active Sponsors and Developers
  • 2.1.4 Pipeline Expansion Trends
  • 2.1.5 Emerging Technology Adoption Trends
• 2.2 Pipeline Metrics Overview
  • 2.2.1 Total Active Emerging Assets
  • 2.2.2 Assets by Clinical Development Phase
  • 2.2.3 Assets by Mechanism of Action
  • 2.2.4 Assets by Modality
  • 2.2.5 Assets by Geography
• 2.3 Historical Progression Analysis
  • 2.3.1 Historical Phase Advancement Trends
  • 2.3.2 Historical Regulatory Outcomes
  • 2.3.3 Clinical Attrition Trends
  • 2.3.4 Development Timeline Trends
  • 2.3.5 Sponsor Success Benchmarking

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Chronic Insomnia Disorder
  • 3.1.2 Acute Insomnia
  • 3.1.3 Comorbid Insomnia
  • 3.1.4 Treatment-Resistant Insomnia
  • 3.1.5 Special Population Insomnia
• 3.2 Disease Burden Assessment
  • 3.2.1 Epidemiology Overview
  • 3.2.2 Healthcare Burden
  • 3.2.3 Economic Impact
  • 3.2.4 Quality of Life Burden
  • 3.2.5 Productivity Loss Assessment
• 3.3 Current Treatment Limitations
  • 3.3.1 Limitations of Sedative-Hypnotics
  • 3.3.2 Dependence and Abuse Concerns
  • 3.3.3 Long-Term Safety Challenges
  • 3.3.4 Residual Daytime Impairment
  • 3.3.5 Treatment Adherence Challenges
• 3.4 Emerging Therapy Opportunities
  • 3.4.1 Mechanism-Based Therapy Opportunities
  • 3.4.2 Precision Medicine Potential
  • 3.4.3 Novel Target Opportunities
  • 3.4.4 Underserved Patient Populations

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Clustering
  • 4.1.1 Dual Orexin Receptor Antagonists (DORAs)
  • 4.1.2 Selective Orexin Receptor Antagonists
  • 4.1.3 GABA-A Receptor Modulators
  • 4.1.4 Melatonin Receptor Agonists
  • 4.1.5 Circadian Rhythm Modulators
  • 4.1.6 Serotonergic Approaches
  • 4.1.7 Histaminergic Targets
  • 4.1.8 Emerging Novel Targets
• 4.2 Innovation Assessment
  • 4.2.1 First-in-Class Emerging Assets
  • 4.2.2 Best-in-Class Competitive Candidates
  • 4.2.3 Differentiated Clinical Profiles
  • 4.2.4 Innovation Density by Mechanism
  • 4.2.5 White Space Opportunity Mapping
• 4.3 Modality Analysis
  • 4.3.1 Small Molecule Therapeutics
  • 4.3.2 Biologic-Based Therapeutics
  • 4.3.3 RNA-Based Therapeutics
  • 4.3.4 Cell Therapy Exploration
  • 4.3.5 Gene Therapy Exploration
  • 4.3.6 Combination Therapy Platforms
• 4.4 Mechanism-Level Competitive Benchmarking
  • 4.4.1 Clinical Differentiation Analysis
  • 4.4.2 Safety Profile Benchmarking
  • 4.4.3 Efficacy Benchmarking
  • 4.4.4 Commercial Differentiation Potential

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Clinical Trial Inventory
  • 5.1.2 Historical Trial Initiation Trends
  • 5.1.3 Trial Completion Trends
  • 5.1.4 Ongoing Recruitment Activity
  • 5.1.5 Planned Clinical Programs
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Benchmarking
  • 5.2.2 Trial Duration Benchmarking
  • 5.2.3 Endpoint Benchmarking
  • 5.2.4 Comparator Selection Trends
  • 5.2.5 Patient Population Selection Trends
• 5.3 Endpoint Intelligence
  • 5.3.1 Wake After Sleep Onset (WASO)
  • 5.3.2 Latency to Persistent Sleep (LPS)
  • 5.3.3 Total Sleep Time (TST)
  • 5.3.4 Daytime Functioning Measures
  • 5.3.5 Patient-Reported Outcomes
  • 5.3.6 Digital Sleep Metrics
• 5.4 Recruitment and Retention Analysis
  • 5.4.1 Recruitment Timelines
  • 5.4.2 Enrollment Rates
  • 5.4.3 Screen Failure Trends
  • 5.4.4 Patient Retention Trends
  • 5.4.5 Dropout Analysis
• 5.5 Success and Failure Intelligence
  • 5.5.1 Clinical Success Rates by Phase
  • 5.5.2 Failure Rates by Mechanism
  • 5.5.3 Regulatory Setback Analysis
  • 5.5.4 Historical Development Lessons
  • 5.5.5 Emerging Risk Factors

6. Pipeline Segmentation Analysis

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Pipeline
    • 6.1.1.1 Asset Inventory and Count
    • 6.1.1.2 Asset-Level Profiles
    • 6.1.1.3 Developer Analysis
    • 6.1.1.4 Mechanism Distribution
    • 6.1.1.5 Probability of Advancement
  • 6.1.2 Phase I Pipeline
    • 6.1.2.1 Asset Inventory and Count
    • 6.1.2.2 Asset-Level Profiles
    • 6.1.2.3 Safety and Tolerability Findings
    • 6.1.2.4 Key Milestone Assessment
    • 6.1.2.5 Probability of Advancement
  • 6.1.3 Phase II Pipeline
    • 6.1.3.1 Asset Inventory and Count
    • 6.1.3.2 Asset-Level Profiles
    • 6.1.3.3 Proof-of-Concept Evaluation
    • 6.1.3.4 Competitive Positioning
    • 6.1.3.5 Probability of Advancement
  • 6.1.4 Phase III Pipeline
    • 6.1.4.1 Asset Inventory and Count
    • 6.1.4.2 Asset-Level Profiles
    • 6.1.4.3 Registrational Strategy Assessment
    • 6.1.4.4 Launch Readiness Evaluation
    • 6.1.4.5 Probability of Approval
  • 6.1.5 Filed and Under Regulatory Review Assets
    • 6.1.5.1 Asset Inventory and Count
    • 6.1.5.2 Regulatory Status Assessment
    • 6.1.5.3 Approval Timeline Outlook
    • 6.1.5.4 Commercial Readiness Assessment
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Orexin-Based Emerging Therapies
  • 6.2.2 GABAergic Emerging Therapies
  • 6.2.3 Circadian Rhythm Modulators
  • 6.2.4 Melatonin-Based Emerging Therapies
  • 6.2.5 Novel Mechanism-Based Emerging Therapies
• 6.3 Pipeline by Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 RNA Therapies
  • 6.3.4 Cell Therapies
  • 6.3.5 Gene Therapies

7. Probability of Success and Risk Analysis

• 7.1 Phase Transition Probability Modeling
  • 7.1.1 Preclinical to Phase I
  • 7.1.2 Phase I to Phase II
  • 7.1.3 Phase II to Phase III
  • 7.1.4 Phase III to Approval
  • 7.1.5 Overall Likelihood of Approval
• 7.2 Risk-Adjusted Pipeline Valuation
  • 7.2.1 Asset-Level Risk Scoring
  • 7.2.2 Mechanism-Based Risk Scoring
  • 7.2.3 Sponsor Execution Risk Assessment
  • 7.2.4 Regulatory Risk Analysis
  • 7.2.5 Commercial Risk Analysis
• 7.3 Attrition Analysis
  • 7.3.1 Historical Attrition Trends
  • 7.3.2 Attrition by Development Phase
  • 7.3.3 Attrition by Mechanism
  • 7.3.4 Attrition by Sponsor Type
  • 7.3.5 Key Failure Drivers
• 7.4 Probability-Weighted Commercial Potential
  • 7.4.1 Risk-Adjusted Revenue Potential
  • 7.4.2 Peak Sales Probability Modeling
  • 7.4.3 Scenario-Based Commercial Forecasts
  • 7.4.4 Portfolio Value Creation Assessment

8. Launch Timeline and Commercial Potential

• 8.1 Approval Timeline Forecasting
  • 8.1.1 Expected Regulatory Submission Timelines
  • 8.1.2 Expected Approval Timelines
  • 8.1.3 Regulatory Milestone Calendar
  • 8.1.4 Launch Readiness Assessment
• 8.2 Launch Sequencing Analysis
  • 8.2.1 Near-Term Emerging Launches
  • 8.2.2 Mid-Term Launch Opportunities
  • 8.2.3 Long-Term Emerging Assets
  • 8.2.4 Competitive Entry Timing
• 8.3 Commercial Opportunity Assessment
  • 8.3.1 Market Access Potential
  • 8.3.2 Pricing Potential
  • 8.3.3 Reimbursement Potential
  • 8.3.4 Adoption Potential
  • 8.3.5 Peak Sales Potential

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Pipeline Strength Assessment
  • 9.1.1 Leading Emerging Therapy Developers
  • 9.1.2 Challenger Companies
  • 9.1.3 Emerging Biotech Innovators
  • 9.1.4 Academic and Research Sponsors
• 9.2 Competitive Benchmarking
  • 9.2.1 Pipeline Breadth Assessment
  • 9.2.2 Pipeline Depth Assessment
  • 9.2.3 Innovation Leadership Assessment
  • 9.2.4 Development Efficiency Benchmarking
• 9.3 Asset Concentration Analysis
  • 9.3.1 Top Emerging Assets by Phase
  • 9.3.2 Top Emerging Assets by Commercial Potential
  • 9.3.3 High-Risk High-Reward Assets
  • 9.3.4 Strategic White Space Opportunities

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Review Environment
  • 10.1.3 Innovation Hubs
  • 10.1.4 Sponsor Concentration
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Review Environment
  • 10.2.3 Innovation Hubs
  • 10.2.4 Sponsor Concentration
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Review Environment
  • 10.3.3 Innovation Hubs
  • 10.3.4 Sponsor Concentration
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Review Environment
  • 10.4.3 Innovation Hubs
  • 10.4.4 Sponsor Concentration
• 10.5 Middle East and Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Review Environment
  • 10.5.3 Innovation Hubs
  • 10.5.4 Sponsor Concentration

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
• 11.2 Canada
  • 11.2.1 Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

Standard Framework for Sections 11.3-11.16

Trial Activity Assessment

Regulatory Timeline Analysis

Key Sponsor Mapping

12. Deals and Investment Landscape

• 12.1 Licensing Transactions
  • 12.1.1 Asset Licensing Trends
  • 12.1.2 Regional Licensing Activity
  • 12.1.3 Mechanism-Specific Licensing Activity
• 12.2 Strategic Collaborations
  • 12.2.1 Co-Development Agreements
  • 12.2.2 Research Collaborations
  • 12.2.3 Platform Partnerships
• 12.3 Mergers and Acquisitions
  • 12.3.1 Asset Acquisition Activity
  • 12.3.2 Pipeline Expansion Transactions
  • 12.3.3 Strategic Consolidation Trends
• 12.4 Funding and Capital Flows
  • 12.4.1 Venture Capital Activity
  • 12.4.2 Private Equity Activity
  • 12.4.3 Public Market Financing
  • 12.4.4 Funding by Development Stage

13. Future Outlook and Strategic Insights

• 13.1 Future Innovation Landscape
  • 13.1.1 Next-Generation Orexin Therapies
  • 13.1.2 Emerging Biological Targets
  • 13.1.3 Precision Sleep Medicine Opportunities
  • 13.1.4 Digital Integration Opportunities
• 13.2 Strategic Opportunity Assessment
  • 13.2.1 Licensing Opportunities
  • 13.2.2 Acquisition Targets
  • 13.2.3 Partnership Opportunities
  • 13.2.4 White Space Opportunities
• 13.3 Long-Term Market Outlook
  • 13.3.1 Emerging Standard-of-Care Evolution
  • 13.3.2 Competitive Dynamics Through Forecast Period
  • 13.3.3 Future Commercial Leaders

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Pipeline Identification Framework
  • 14.1.2 Asset Inclusion and Exclusion Criteria
  • 14.1.3 Data Validation Methodology
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Register
  • 14.2.3 Company Pipeline Disclosures
  • 14.2.4 Regulatory Filings
  • 14.2.5 Scientific Publications
• 14.3 Forecasting and Modeling Methodology
  • 14.3.1 Probability of Success Model
  • 14.3.2 Risk Adjustment Methodology
  • 14.3.3 Revenue Forecasting Framework
  • 14.3.4 Scenario Modeling Approach
• 14.4 Validation and Limitations
  • 14.4.1 Data Quality Assessment
  • 14.4.2 Assumptions Framework
  • 14.4.3 Model Limitations
  • 14.4.4 Verification Protocol